Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 22, 2022 | June 24, 2022 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 24, 2023 | May 25, 2023 |
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | Director | July 14, 2017 | July 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2022-06-22 transaction · row 1
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 40,000 · Balance 40,000 F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2032-06-22 | Direct | 65,000 |
Reported balance
After 2022-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-22 · Grant · Acquired 65,000 · Balance 65,000 F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock.
F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
Karyopharm Therapeutics Inc.
Report date May 24, 2023 · Filed May 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2033-05-23 | Direct | 34,000 |
Reported balance
After 2023-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-24 · Grant · Acquired 34,000 · Balance 34,000 F1: This option vests as to 100% of the underlying shares on May 24, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 100% of the underlying shares on May 24, 2024.
Orexigen Therapeutics, Inc.
Report date July 14, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2027-07-13 | Direct | 5,000 |
Reported balance
After 2017-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-14 · Grant · Acquired 5,000 · Balance 5,000 F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2023 Filed May 25, 2023 16:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-032140 · doc4.xml · derivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:31 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001485003-22-000084 · wf-form4_165610988351357.xml · derivative · entry 2 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:31 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-22-000084 · wf-form4_165610988351357.xml · nonDerivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 10,995 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030970 · doc4.xml · derivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,995 Underlying: Common Stock · 10,995 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 10:37 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 47,800 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-21-068261 · doc4.xml · derivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,800 Underlying: Common Stock · 47,800 shares Expires 2031-12-02 F1 · derivative.exercise_date: This option was granted on December 3, 2021. The shares underlying the option vest as to one-third (1/3) of the shares on December 3, 2022 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:37 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 185,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001485003-21-000158 · wf-form4_162690342009283.xml · derivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2031-07-20 F1 · derivative.exercise_date: The option was granted on July 20, 2021 and vests monthly in equal amounts over a three-year period following the grant date. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion, the compensation committee of Sesen Bio, Inc. (the "Company") recommended to the Company's board of directors, and the board of directors approved, the amount of the initial grant to the reporting person in connection with the reporting person's appointment as a non-employee director. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 19:38 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-17-045599 · doc4.xml · derivative · entry 1 Honig Peter · CIK 0001484780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.